Filing summary
Identity note: The supplied metadata names Oruka Therapeutics, Inc., but the filing is for ARCA biopharma, Inc. (Nasdaq: ABIO). This summary describes ARCA’s Form 10-Q for the quarter ended September 30, 2019, filed November 6, 2019.
Business context and reporting period
ARCA is a pre-revenue biopharmaceutical company developing genetically targeted cardiovascular treatments. Its lead candidate, Gencaro, is being developed for atrial fibrillation in certain heart-failure patients; AB171 is an earlier-stage candidate. The report covers the three and nine months ended September 30, 2019. ARCA reported no product revenue.
Financial results and liquidity
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Research and development | $347,000 | $740,000 | $1.449 million | $3.614 million |
| General and administrative | $900,000 | $922,000 | $3.087 million | $2.977 million |
| Net loss | $1.156 million | $1.593 million | $4.256 million | $6.444 million |
| Operating cash used | Not stated for quarter | Not stated for quarter | $3.643 million | $6.901 million |
At September 30, cash and cash equivalents were $9.645 million, versus $6.608 million at December 31, 2018. Current assets were $9.904 million and current liabilities $1.150 million; stockholders’ equity was $8.799 million. The balance sheet lists no material borrowing balance, although cash-flow disclosures show repayments under a vendor-financing arrangement and the filing does not clearly state its remaining balance. Interest expense was $7,000 for the first nine months. With no revenue, profit margins are not meaningful.
Cash increased by $3.037 million in the first nine months, principally from $6.9 million of net proceeds from common-stock sales, offset by operating cash use and vendor-financing repayments. Financing activities provided $6.682 million net. The company’s ATM equity offering was fully utilized under the relevant prospectus by September 30; by November 1, it reported approximately $17.4 million in aggregate gross proceeds and $16.4 million net proceeds from the offering.
Changes versus the prior comparable periods
- Q3 net loss narrowed by $437,000 year over year; nine-month net loss narrowed by $2.188 million.
- R&D expense fell by $393,000 in Q3 and $2.165 million for the nine months, primarily because the GENETIC-AF trial was completed in 2018.
- Nine-month G&A increased by $110,000, while Q3 G&A was broadly unchanged.
- Cash rose from year-end 2018, supported by equity issuance; shares outstanding increased from 773,558 at December 31, 2018 to 1,594,070 at September 30, 2019. The filing also reflects the April 2019 1-for-18 reverse stock split.
Outlook, commentary, and key risks
- Management estimated that cash, assuming its projected cost structure and potential cost reductions, would fund operations through the third quarter of 2020. It also concluded that substantial doubt existed about the company’s ability to continue as a going concern for one year from issuance of the financial statements.
- ARCA said it needs substantial additional capital or a strategic transaction to fund operations and further development. Failure to obtain funding could force it to delay or stop development or cease operations. Equity financing could significantly dilute shareholders; debt could have priority over equity and impose restrictive covenants.
- Subject to significant additional financing, ARCA anticipated starting the approximately 400-patient PRECISION-AF Phase 3 trial in the first quarter of 2020. The FDA had agreed to the trial’s protocol through a Special Protocol Assessment, but the filing emphasizes that an SPA does not guarantee trial success or approval.
- Management expected 2019 R&D expense to be below 2018 levels, with G&A broadly consistent with 2018. In May 2019, the company reduced personnel costs, including executive salaries.
- GENETIC-AF showed similar treatment benefit overall versus the active comparator; favorable results cited by management came from specified subgroup analyses. Investors should distinguish these subgroup findings from the overall trial result.
- Other material risks include clinical-trial enrollment and execution, regulatory and companion-diagnostic approval, reliance on third parties, intellectual-property and licensing obligations, Nasdaq listing requirements, and the company’s limited operating resources. No legal proceedings were reported.
Important facts for investors to verify
- Confirm the issuer: this is an ARCA biopharma filing, not a filing identified as Oruka Therapeutics.
- Assess the going-concern warning, cash runway assumptions, planned cost reductions, and financing or strategic-transaction prospects.
- Check whether PRECISION-AF was funded and initiated, and evaluate its final protocol, enrollment criteria, endpoints, and regulatory status.
- Review subsequent share issuance, dilution, Nasdaq listing compliance, and remaining financing capacity after the ATM offering.
- Evaluate the full GENETIC-AF results alongside the subgroup analyses, and verify Gencaro’s licensing, royalty, and milestone terms.